Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent
- PMID: 19894727
- DOI: 10.1021/jm9013828
Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent
Abstract
Design and synthesis of a series of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as potent and selective inhibitors of the mammalian target of rapamycin (mTOR) are described. Optimization of the 6-aryl substituent led to the discovery of inhibitors carrying 6-ureidophenyl groups, the first reported active site inhibitors of mTOR with subnanomolar inhibitory concentrations. The data presented in this paper show that 6-arylureidophenyl substituents led to potent mixed inhibitors of mTOR and phosphatidylinositol 3-kinase alpha (PI3K-alpha), whereas 6-alkylureidophenyl appendages gave highly selective mTOR inhibitors. Combination of 6-alkylureidophenyl groups with 1-carbamoylpiperidine substitution resulted in compounds with subnanomolar IC(50) against mTOR and greater than 1000-fold selectivity over PI3K-alpha. In addition, structure based drug design resulted in the preparation of several 6-arylureidophenyl-1H-pyrazolo[3,4-d]pyrimidines, substituted in the 4-position of the arylureido moiety with water solubilizing groups. These compounds combined potent mTOR inhibition (IC(50) < 1 nM) with unprecedented activity in cellular proliferation assays (IC(50) < 1 nM).
Similar articles
-
Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).Bioorg Med Chem Lett. 2010 Jan 15;20(2):640-3. doi: 10.1016/j.bmcl.2009.11.050. Epub 2009 Dec 4. Bioorg Med Chem Lett. 2010. PMID: 19963384
-
Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.J Med Chem. 2009 Nov 26;52(22):7081-9. doi: 10.1021/jm9012642. J Med Chem. 2009. PMID: 19848404
-
Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors.J Med Chem. 2009 Dec 24;52(24):7942-5. doi: 10.1021/jm901415x. J Med Chem. 2009. PMID: 19916508
-
Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.J Pharm Belg. 1997 Mar-Apr;52(2):88-96. J Pharm Belg. 1997. PMID: 9193132 Review.
-
Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.Curr Opin Drug Discov Devel. 2010 Jul;13(4):428-40. Curr Opin Drug Discov Devel. 2010. PMID: 20597028 Review.
Cited by
-
Discovery and biological evaluation of nitrofuranyl-pyrazolopyrimidine hybrid conjugates as potent antimicrobial agents targeting Staphylococcus aureus and methicillin-resistant S. aureus.RSC Med Chem. 2024 Dec 26. doi: 10.1039/d4md00826j. Online ahead of print. RSC Med Chem. 2024. PMID: 39829972 Free PMC article.
-
A selectivity study on mTOR/PI3Kα inhibitors by homology modeling and 3D-QSAR.J Mol Model. 2012 Jan;18(1):171-86. doi: 10.1007/s00894-011-1034-3. Epub 2011 Apr 27. J Mol Model. 2012. PMID: 21523553
-
Recent advances and limitations of mTOR inhibitors in the treatment of cancer.Cancer Cell Int. 2022 Sep 15;22(1):284. doi: 10.1186/s12935-022-02706-8. Cancer Cell Int. 2022. PMID: 36109789 Free PMC article. Review.
-
mTOR Inhibitors at a Glance.Mol Cell Pharmacol. 2015;7(2):15-20. Mol Cell Pharmacol. 2015. PMID: 27134695 Free PMC article.
-
Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones.Bioorg Med Chem Lett. 2016 Apr 1;26(7):1827-1830. doi: 10.1016/j.bmcl.2016.02.030. Epub 2016 Feb 16. Bioorg Med Chem Lett. 2016. PMID: 26916440 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous